Skip to main content

Biotechnology company



posted third-quarter earnings that topped analysts' expectations, citing benefits from its acquisition of


and its recent


licensing agreement.

The Emeryville, Calif., company earned $43 million, or 23 cents a share, up from $33 million, or 17 cents a share, in last year's quarter. A

First Call/Thomson Financial

survey of 13 analysts produced a consensus estimate of 17 cents a share.

Total revenue for the quarter rose 8% to $221 million from $204 million last year.